Snyder Rita A, Abarca Jacob, Meza Jane L, Rothschild Jeffrey M, Rizos Albert, Bates David W
College of Nursing, University of Nebraska Medical Center, Omaha, NE, USA.
Pharmacoepidemiol Drug Saf. 2007 Sep;16(9):1006-13. doi: 10.1002/pds.1423.
Adapted National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) Index criteria were used in a study undertaken to evaluate commercial computerized provider order entry (CPOE) system impact on community hospital medication errors. This article describes: (1) adaptation of the Index, (2) classification criteria and processes used to assess the adapted Index, and (3) inter-rater reliability results.
A random sample of 130 (17%) of 2251 medication safety events (MSEs) were classified based on event type, that is, adverse drug event (ADE) or potential ADE (PADE); preventability, that is, 'yes' or 'no,' and outcome severity. Event outcome severity was categorized using adapted Index categories E-I (ADEs) and B-D (PADEs). Decision rules were used for rule-based classification, while an MSE Case Review Panel used judgment-based classification when decision rules did not apply. Inter-rater reliability for both classification approaches was assessed with kappa coefficients, percentage agreement, and confidence intervals (CI).
Level of agreement was substantial for both rule-based and judgment-based MSE classification for event type (6 = 0.70-0.90), preventability (6 = 0.67-0.82), and decision rule application (6 = 0.79). Rule-based agreement for ADE and PADE severity was almost perfect for discrete (6 = 0.83-0.84) and combined (6 = 0.87-0.90) Index categories. Judgment-based agreement was substantial for discrete (6 = 0.63-0.67) and combined (6 = 0.66-0.84) Index categories.
The adapted Index yielded substantial agreement for event type, preventability, and severity. Adaptation of the Index to support classification of non-preventable ADEs was an important improvement.
在一项旨在评估商业计算机化医嘱录入(CPOE)系统对社区医院用药错误影响的研究中,采用了改编后的国家用药错误报告与预防协调委员会(NCC MERP)指数标准。本文描述了:(1)该指数的改编,(2)用于评估改编后指数的分类标准和流程,以及(3)评分者间信度结果。
从2251起用药安全事件(MSE)中随机抽取130起(17%),根据事件类型(即药品不良事件[ADE]或潜在药品不良事件[PADE])、可预防性(即“是”或“否”)和结果严重程度进行分类。事件结果严重程度使用改编后的指数类别E-I(ADE)和B-D(PADE)进行分类。决策规则用于基于规则的分类,而当决策规则不适用时,MSE病例审查小组使用基于判断的分类。两种分类方法的评分者间信度通过kappa系数、百分比一致性和置信区间(CI)进行评估。
对于基于规则和基于判断的MSE分类,在事件类型(κ = 0.70 - 0.90)、可预防性(κ = 0.67 - 0.82)和决策规则应用(κ = 0.79)方面,一致性水平较高。对于ADE和PADE严重程度,基于规则的离散指数类别(κ = 0.83 - 0.84)和合并指数类别(κ = 0.87 - 0.90)的一致性几乎完美。基于判断的离散指数类别(κ = 0.63 - 0.67)和合并指数类别(κ = 0.66 - 0.84)的一致性较高。
改编后的指数在事件类型、可预防性和严重程度方面达成了较高的一致性。对指数进行改编以支持对不可预防的ADE进行分类是一项重要的改进。